Moderna, Inc.: Target Price Consensus and Analysts Recommendations | MRNA | US60770K1079

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

57.80USD

Average target price

42.25USD

Spread / Average Target

-26.90%

High Price Target

135.00USD

Spread / Highest target

+133.56%

Low Price Target

12.00USD

Spread / Lowest Target

-79.24%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Rothschild & Co Redburn
Bernstein
RBC Capital Markets
Jefferies & Co.
Leerink Partners
TD Cowen
Wolfe Research
Goldman Sachs
UBS
BofA Securities
Morgan Stanley
Berenberg Bank
Piper Sandler
Barclays
Evercore ISI
Citigroup
JPMorgan Chase
DBS Bank
Deutsche Bank Securities
Redburn Atlantic
HSBC
Argus
Baptista Research
BERENBERG	Harry Gillis
Brookline Capital Markets
Oppenheimer
Oddo BHF
JPMORGAN	Jessica Fye
RBC	Luca Issi
Redburn
Canaccord Genuity
William Blair & Co.
Guggenheim
SVB Securities LLC
Cowen
Chardan Research
SVB Leerink
Chardan
J.P. Morgan Chase

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

57.80USD

Average target price

42.25USD

Spread / Average Target

-26.90%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 05/03/2026 am IST			Pre-market 05:20:23 pm
57.80 ^USD	+15.99%		57.26	-0.94%

05:15pm	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
05:32am	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE

05:15pm	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
27/02	Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating	MT
26/02	Analyst recommendations: Spotify, Gartner, Godaddy, Medline, Moderna…
17/02	Bernstein Adjusts Price Target on Moderna to $45 From $35, Maintains Market Perform Rating	MT
17/02	RBC Capital Adjusts Price Target on Moderna to $30 From $25, Maintains Sector Perform Rating	MT
17/02	Analyst recommendations: Accenture, Dollar Tree, DraftKings, Moderna, Walmart…
16/02	Berenberg Reiterates Sanofi at Buy on 'Significant' Share Discount	MT
13/02	RBC Raises Price Target on Moderna to $30 From $25, Keeps Sector Perform Rating	MT
13/02	Jefferies Raises Price Target on Moderna to $37 From $30	MT
11/02	Leerink Partners Adjusts Moderna PT to $12 From $17, Maintains Underperform Rating	MT
30/01	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
29/01	TD Cowen Adjusts Moderna Price Target to $40 From $25, Maintains Hold Rating	MT
28/01	Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating	MT
23/01	Bernstein Adjusts Price Target on Moderna to $35 From $25, Maintains Market Perform Rating	MT
23/01	Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna…
12/01	Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating	MT
07/01	UBS Downgrades Moderna to Neutral From Buy, Cuts Price Target to $34 From $40	MT
06/01	BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating	MT
12/12	Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating	MT
12/12	Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target	MT
26/11	Berenberg Trims Price Target on Moderna to $26 From $28, Keeps Hold Rating	MT
21/11	Piper Sandler Adjusts Price Target on Moderna to $63 From $69, Maintains Overweight Rating	MT
21/11	Leerink Partners Adjusts Price Target on Moderna to $18 From $15, Maintains Underperform Rating	MT
21/11	RBC Cuts Price Target on Moderna to $25 From $28, Keeps Sector Perform Rating	MT
21/11	Wolfe Research Adjusts Price Target on Moderna to $17 From $16, Maintains Underperform Rating	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MODERNA, INC.					-26.9%
	REGENERON PHARMACEUTICALS, INC.					+10.57%
	UCB					+8.17%
	SAMSUNG BIOLOGICS CO.,LTD.					+48.68%
	CSL LIMITED					+47.76%
	BIOGEN INC.					+8.28%
	INCYTE CORPORATION					+8.33%
	INNOVENT BIOLOGICS, INC.					+49.81%
	SWEDISH ORPHAN BIOVITRUM AB					+9.68%
	ALTEOGEN INC.					+31.02%
	Average					+19.54%
	Weighted average by Cap.					+20.41%

Consensus Moderna, Inc.

Equities

MRNA

US60770K1079

Pharmaceuticals

Evolution of the Average Target: Moderna, Inc.

Evolution of the Target Price: Moderna, Inc.

Changes in Analyst Recommendations: Moderna, Inc.

Analysts' recommendations: Moderna, Inc.

Sector Comparison:

Analysts' Consensus

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Analysts' Consensus

Quarterly revenue - Rate of surprise

Consensus Moderna, Inc.

Equities

MRNA

US60770K1079

Pharmaceuticals

Evolution of the Average Target: Moderna, Inc.

Evolution of the Target Price: Moderna, Inc.

Changes in Analyst Recommendations: Moderna, Inc.

Analysts' recommendations: Moderna, Inc.

Sector Comparison: HealthcarePharmaceuticals & Medical ResearchPharmaceuticalsPharmaceuticalsBiopharmaceuticals

Analysts' Consensus

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sector Comparison: